Cargando…

Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation

There is no consensus regarding which therapeutic option is better and/or safer for treating hemodialysis (HD) patients with hepatocellular carcinoma (HCC). The present study compared surgical resection (Hx) and radiofrequency ablation (RFA) with regard to therapeutic efficacy in HD patients with HC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiraoka, Atsushi, Kumada, Takashi, Michitaka, Kojiro, Toyoda, Hidenori, Tada, Toshifumi, Takaguchi, Koichi, Tsuji, Kunihiko, Itobayashi, Ei, Takizawa, Daichi, Hirooka, Masashi, Koizumi, Yohei, Ochi, Hironori, Joko, Koji, Kisaka, Yoshiyasu, Shimizu, Yuko, Tajiri, Kazuto, Tani, Joji, Taniguchi, Tatsuya, Toshimori, Akiko, Fujioka, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374965/ https://www.ncbi.nlm.nih.gov/pubmed/28413650 http://dx.doi.org/10.3892/mco.2017.1192

Ejemplares similares

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2018)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan
por: Tada, Toshifumi, et al.
Publicado: (2017)

C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2022)

Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
por: Tada, Toshifumi, et al.
Publicado: (2020)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
por: Tada, Toshifumi, et al.
Publicado: (2022)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022)

Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma
por: Kariyama, Kazuya, et al.
Publicado: (2019)

AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy
por: Watanabe, Takao, et al.
Publicado: (2021)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality
por: Hiraoka, Atsushi, et al.
Publicado: (2023)

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Tanaka, Kazunari, et al.
Publicado: (2023)

Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
por: Watanabe, Takao, et al.
Publicado: (2023)

The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria
por: Ochi, Hironori, et al.
Publicado: (2020)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
por: Watanabe, Takao, et al.
Publicado: (2016)

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2019)

Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response
por: Toyoda, Hidenori, et al.
Publicado: (2021)

Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation
por: Hiraoka, Atsushi, et al.
Publicado: (2015)

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
por: Rimini, M., et al.
Publicado: (2021)

Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2011)

Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
por: Tada, Toshifumi, et al.
Publicado: (2017)

Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy
por: Toyoda, Hidenori, et al.
Publicado: (2014)

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
por: Atsukawa, Masanori, et al.
Publicado: (2020)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
por: Chuma, Makoto, et al.
Publicado: (2020)

Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus
por: Tachi, Yoshihiko, et al.
Publicado: (2015)

Natural history of liver‐related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model
por: Tada, Toshifumi, et al.
Publicado: (2019)

Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus
por: Kumada, Takashi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g4prrth2c3oi5j9m1pk266jgun